ATNM Valuation

Actinium Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.650

+0.04(2.484%)1D

Overview
Forecast
Valuation
Earnings

ATNM Relative Valuation

ATNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATNM is overvalued; if below, it's undervalued.

Historical Valuation

Actinium Pharmaceuticals Inc (ATNM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.91 is considered Undervalued compared with the five-year average of -5.21. The fair price of Actinium Pharmaceuticals Inc (ATNM) is between 1.99 to 2.93 according to relative valuation methord. Compared to the current price of 1.61 USD , Actinium Pharmaceuticals Inc is Undervalued By 19.3%.

Relative Value

Fair Zone

1.99-2.93

Current Price：1.61

19.3%

Undervalued

-2.30

Trailing

Forward

0.16

EV/EBITDA

Actinium Pharmaceuticals Inc. (ATNM) has a current EV/EBITDA of 0.16. The 5-year average EV/EBITDA is -1.96. The thresholds are as follows: Strongly Undervalued below -5.23, Undervalued between -5.23 and -3.59, Fairly Valued between -0.32 and -3.59, Overvalued between -0.32 and 1.32, and Strongly Overvalued above 1.32. The current Forward EV/EBITDA of 0.16 falls within the Overvalued range.

0.32

EV/EBIT

Actinium Pharmaceuticals Inc. (ATNM) has a current EV/EBIT of 0.32. The 5-year average EV/EBIT is -1.90. The thresholds are as follows: Strongly Undervalued below -6.54, Undervalued between -6.54 and -4.22, Fairly Valued between 0.42 and -4.22, Overvalued between 0.42 and 2.74, and Strongly Overvalued above 2.74. The current Forward EV/EBIT of 0.32 falls within the Historic Trend Line -Fairly Valued range.

2.91

Actinium Pharmaceuticals Inc. (ATNM) has a current PS of 2.91. The 5-year average PS is 220.99. The thresholds are as follows: Strongly Undervalued below -654.45, Undervalued between -654.45 and -216.73, Fairly Valued between 658.71 and -216.73, Overvalued between 658.71 and 1096.43, and Strongly Overvalued above 1096.43. The current Forward PS of 2.91 falls within the Historic Trend Line -Fairly Valued range.

-1.41

P/OCF

Actinium Pharmaceuticals Inc. (ATNM) has a current P/OCF of -1.41. The 5-year average P/OCF is -2.25. The thresholds are as follows: Strongly Undervalued below -15.74, Undervalued between -15.74 and -9.00, Fairly Valued between 4.49 and -9.00, Overvalued between 4.49 and 11.23, and Strongly Overvalued above 11.23. The current Forward P/OCF of -1.41 falls within the Historic Trend Line -Fairly Valued range.

-1.59

P/FCF

Actinium Pharmaceuticals Inc. (ATNM) has a current P/FCF of -1.59. The 5-year average P/FCF is -4.02. The thresholds are as follows: Strongly Undervalued below -37.58, Undervalued between -37.58 and -20.80, Fairly Valued between 12.77 and -20.80, Overvalued between 12.77 and 29.55, and Strongly Overvalued above 29.55. The current Forward P/FCF of -1.59 falls within the Historic Trend Line -Fairly Valued range.

Actinium Pharmaceuticals Inc (ATNM) has a current Price-to-Book (P/B) ratio of 2.64. Compared to its 3-year average P/B ratio of 3.16 , the current P/B ratio is approximately -16.40% higher. Relative to its 5-year average P/B ratio of 2.75, the current P/B ratio is about -3.89% higher. Actinium Pharmaceuticals Inc (ATNM) has a Forward Free Cash Flow (FCF) yield of approximately -59.27%. Compared to its 3-year average FCF yield of -34.83%, the current FCF yield is approximately 70.16% lower. Relative to its 5-year average FCF yield of -26.10% , the current FCF yield is about 127.12% lower.

2.64

P/B

Median3y

3.16

Median5y

2.75

-59.27

FCF Yield

Median3y

-34.83

Median5y

-26.10

Competitors Valuation Multiple

The average P/S ratio for ATNM's competitors is 14.71, providing a benchmark for relative valuation. Actinium Pharmaceuticals Inc Corp (ATNM) exhibits a P/S ratio of 2.91, which is -80.23% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATNM.A

Actinium Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc

Relmada Therapeutics Inc

Loss

50.12M

JUNS.O

Jupiter Neurosciences Inc

Performance Decomposition

Market capitalization of ATNM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATNM in the past 1 year is driven by Unknown.